体重指数负向影响英夫利昔单抗在类风湿关节炎中的疗效
Body Mass Index Negatively Influences the Response to Infliximab in Rheumatoid Arthritis.
Background/Purpose: The excess of adipose tissue in obese individuals
may have immunomodulating properties and pharmacokinetics consequences.
Adipose tissue is potentially involved in the regulation of inflammation
in rheumatoid arthritis (RA). Recently, an exploratory study suggested
that body mass index (BMI) could affect infliximab (IFX) treatment responses
in RA patients (1)
The aim of this study was to investigate whether body mass index (BMI)
affects the response to IFX in RA patients
Methods: In this retrospective study were included RA patients
fulfilling the ACR 1987 criteria and receiving infliximab therapy. All
individuals provided informed written consent as approved by the local
ethic committee board. The BMI was assessed before the initiation of
IFX treatment (3 mg/kg intravenously). After 6 months of treatment,
changes in disease activity (DAS28) were assessed. The primary end point
was the EULAR DAS28 response. The following covariates were included
for the analysis: gender, anti-CCP antibodies and RF status, mean
disease duration, erythrocyte sedimentation rate (ESR), CRP level,
DAS28, concomitant DMARDS therapy and corticosteroids consummation.
Results: A total of 73 RA patients (age: 48.5 10.5 years, 82% of
females, disease duration: 8.8 6.9 years, 77% RF , 86% anti-CCP )
were included. At M0, BMI was 27.1 6.9 kg/m2. Patients were
classified in 3 distinct groups according to their BMI: normal (BMI 25
kg/m2), overweight (BMI [25–30] kg/m2) and obesity (BMI >30 kg/m2).
At baseline no difference was observed between the 3 BMI subgroups
according to the RA covariates, notably the DAS28. The EULAR
non-response was found to be only influenced by 2 independent factors: a
lower initial DAS28 (4.9 1.4 vs 5.9 1.0, P 0,012) and a higher BMI
(29.5 8.7 vs 25.2 3.9 kg/m2, P 0.013). When the 3 BMI subgroups
were independently analyzed, the negative influence of BMI on response
to IFX was only found in obese patients (P 0.008, OR 5.2 [1.3–23.2])
in comparison to normal BMI group.
Conclusion: Our study supports the previously reported negative
correlation between BMI and infliximab response in RA. Further prospective
studies, including assessment of the fat mass, pharmacokinetics and
adipokines dosages are mandatory to elucidate the role of obesity and the
fat mass in modulating the RA IFX response.